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Background. SCN5A encodes the a-subunit (Nav1.5) of the principle Na
+ channel in the human heart. Genetic lesions in SCN5A
can cause congenital long QT syndrome (LQTS) variant 3 (LQT-3) in adults by disrupting inactivation of the Nav1.5 channel.
Pharmacological targeting of mutation-altered Na
+ channels has proven promising in developing a gene-specific therapeutic
strategy to manage specifically this LQTS variant. SCN5A mutations that cause similar channel dysfunction may also contribute
to sudden infant death syndrome (SIDS) and other arrhythmias in newborns, but the prevalence, impact, and therapeutic
management of SCN5A mutations may be distinct in infants compared with adults. Methods and Results. Here, in
a multidisciplinary approach, we report a de novo SCN5A mutation (F1473C) discovered in a newborn presenting with extreme
QT prolongation and differential responses to the Na
+ channel blockers flecainide and mexiletine. Our goal was to determine
the Na
+ channel phenotype caused by this severe mutation and to determine whether distinct effects of different Na
+ channel
blockers on mutant channel activity provide a mechanistic understanding of the distinct therapeutic responsiveness of the
mutation carrier. Sequence analysis of the proband revealed the novel missense SCN5A mutation (F1473C) and a common
variant in KCNH2 (K897T). Patch clamp analysis of HEK 293 cells transiently transfected with wild-type or mutant Na
+ channels
revealed significant changes in channel biophysics, all contributing to the proband’s phenotype as predicted by in silico
modeling. Furthermore, subtle differences in drug action were detected in correcting mutant channel activity that, together
with both the known genetic background and age of the patient, contribute to the distinct therapeutic responses observed
clinically. Significance. The results of our study provide further evidence of the grave vulnerability of newborns to Na
+
channel defects and suggest that both genetic background and age are particularly important in developing a mutation-
specific therapeutic personalized approach to manage disorders in the young.
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INTRODUCTION
The long QT syndrome (LQTS), a relatively uncommon (1 in
2500) genetic disorder associated with life-threatening arrhyth-
mias, is an example of a channelopathy that has provided a wealth
of information about fundamental mechanisms underlying human
cardiac electrophysiology[1]. LQTS is currently associated with
mutations in 10 different genes[1–3]. LQT variant 3 (LQT-3) is
caused by mutations in SCN5A, the gene coding for the alpha
subunit (NaV1.5) of the primary cardiac voltage-gated Na
+
channel in the human heart. Despite a relatively common
phenotype (delayed repolarization reflected in QT prolongation),
therapeutic strategies have been developed that are dictated by
molecular etiology. Na
+ channel blockers such as mexiletine and
flecainide are effective in treating LQT-3 patients due to
preferential inhibition of mutant Na
+ channel activity[4,5].
Furthermore, current evidence suggests that mutations in ion
channels may also contribute to sudden infant death syndrome
(SIDS) and other cardiac arrhythmias in newborns, and that the
frequency, severity, and treatment of SCN5A mutations may be
distinct in infants compared with adults[6,7,8–11]
Here we report investigation of a de novo SCN5A mutation
discovered in a newborn who had presented with extreme QT
prolongation (approximately 800 ms); 2:1 heart block; and differen-
tial responses to the Na
+ channel blockers lidocaine, mexiletine, and
flecainide. Also found in the proband was common polymorphism
(K897T) in KCNH2, the gene coding for the HERG potassium
channel which contributes to control of ventricular repolarization.
Our results reveal multiple biophysical changes in Na
+ channel
gating induced by the F1473C mutation that all contribute to
delayed repolarization of cellular action potentials and are consistent
with the pronounced phenotype of the patient. Furthermore our
data suggest an important role of the KCNH2 polymorphism and
developmentally-related expression of background ion channels in
boththetherapeutic responseand diseasephenotype ofthe proband.
RESULTS
Clinical profile
The proband was a full term newborn infant boy with a prenatal
history significant for fetal bradycardia of unclear etiology with
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arrhythmias, long QT syndrome, or sudden death. His ECG
demonstrated 2:1 AV block (atrial rate of 108 and ventricular rate
of 54) with a corrected QTC of roughly 825 ms (Fig 1A). Multiple
short episodes of torsades de pointes were documented and treated
initially with IV magnesium and esmolol. Because review of the
ECG suggested a possible SCN5A mutation based upon the
morphology of the QT interval, the patient was given a test dose of
IV lidocaine (1 mg/kg) which resulted in a profound drop in the
corrected QT interval to less than 460ms within 15 seconds of the
bolus dose (Fig. 1B). Approximately 30–45 minutes after this dose,
the QT interval lengthened to roughly 550 ms with intermittent
2:1 conduction. In an attempt to convert the patient to oral Na
+
channel blockers, flecainide was administered with no appreciable
change in the QT interval and with continued incidences of
torsades. Mexilitene was ineffective at lower doses (1–3 mg/kg/
dose po q 6 hours), but at higher doses (,6 mg/kg/dose)
shortened the QT interval (,550–600 ms) similarly to IV
lidocaine. However, the patient continued to have 1–5 short
episodes of torsades each day which led to a dual chamber
implantable cardioverter defibrillator/pacemaker being implanted
epicardially, and it was observed that with ventricular pacing (dual
mode pacing with a lower rate limit of 125/minute) there was
marked reduction in episodes of torsades. On a regimen of oral
beta blockade at high dose (,4–5 mg/kg/day of propranolol/
inderal) with high dose mexiletine, oral magnesium supplementa-
tion and AV sequential pacing, the infant was ultimately
discharged from the hospital at approximately 3 months of age.
There was no family history of prolonged QT, syncope,
presyncope, or sudden death. Both parents had screening ECGs
with normal QT intervals. This was the parents’ only child. The
family was of Italian and Portugese ancestory.
Genetics
Sequence analysis of the proband identified a 4418T=.G SCN5A
variant resulting in a F1473C missense mutation in Nav1.5
Figure 1. Clinical and genetic profile of the proband. A. Baseline ECG recording reporting a QTc of approximately 825 ms. Note 2:1 AV block. B.
RecordingafterinfusionwithIVlidocaine(seetext).QTcisapproximately 450and2:1 blockisabsent. C.ChromatogramsofDNAsequences:theproband
but neither the mother nor father has a 4418 T=.Gi nSCN5A resulting in a substitution of cytsteine for phenylalanine at amino acid 1473 in Nav1.5.
doi:10.1371/journal.pone.0001258.g001
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A=.C KCNH2 polymorphism producing a missense K897T
variant in the HERG channel protein. No mutations were
identified in KCNQ1 (codes for the a subunit of the slowly-
activating IKS channel), KCNE1(codes for the b subunit of the IKS
potassium channel),o rKCNE2 (codes for the b subunit of the
rectifying IKr potasium channel) or other channel-related LQTS
genes. Neither parent was found to have the F1473C mutation.
The father was homozygous for the K897 KCNH2, and the mother
was homozygous for the T897 KCNH2 polymorphism. Micro-
satellite markers confirmed maternity and paternity and establish
F1473C SCN5A as a de novo mutation. None of the 100
Caucasian controls were found to carry the F1473C mutation.
Biophysical Consequences of the F1473C mutation:
multiple mechanisms contribute to delayed
repolarization
The severity of the clinical phenotype, the differential response to
pharmacological agents, and the location of this mutation within
Figure 2. The F1473C mutation increases non-inactivating late current. Whole-cell wild type (WT, A) and mutant (F1473C, B) Na
+ channel currents
at 210 mV (200 ms pulses applied from a 2100 mV holding potential at 0.5 Hz). Shown are averaged raw TTX sensitive traces (WT, n=11; F1743C,
n=31). C. Averaged WT and F1473C currents normalized to peak current and superimposed at high (left) and low (inset) gain (WT n=11, F1473C
n=31). D. Bar graph representing mean +/2 S.E.M. percentage of current remaining at 200 ms with respect to peak current for both WT and F1473C
(WT n=11, F1473C n=31); * p,,0.001.
doi:10.1371/journal.pone.0001258.g002
Figure 3. The F1473C mutation does not affect the voltage dependence of Na
+ channel activation. A. Mean current voltage relationships recorded
in low external sodium solution (Methods S1) in response to 25 ms voltage pulses from 280 mV to +75 mV (5 mV increments) for WT (n=13, open
triangles) and F1473C (n=7, closed squares). B. Mean activation curves obtained from data in A, for WT (open) and F1473C channels (filled) show no
affect of the F1473C mutation on the voltage dependence of activation (see text for details).
doi:10.1371/journal.pone.0001258.g003
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biophysical consequences of the F1473C mutation of particular
interest to us. Figure 2 summarizes the first set of parameters we
examined using standard whole cell patch clamp recording
procedures and results of experiments that were designed to focus
on potential effects of the mutation on currents recorded during
prolonged depolarization. These currents will be referred to as late
Na
+ channel currents. Figure 2A and B compare averaged raw
TTX-sensitive current traces recorded in HEK 293 cells
expressing WT (A) and F1473C mutant (B) Na
+ channels at
sufficiently low gain to capture peak Na
+ channel currents. In
order to detect potential mutation-induced physiologically-signif-
icant changes in Na
+ channel activity during prolonged de-
polarization it is necessary to visualize currents at high recoding
gains, and to compare putative mutation-induced channel
dysfunction to other disease-related mutations, it is useful to
display currents normalized to peak Na
+ channel currents. This
analysis is presented Figure 2C which shows low (left traces) and
high (inset) gain recordings of superimposed averaged and
normalized TTX sensitive current traces recorded at 210 mV
in cells expressing WT and F1473C (arrow) channels. The impact
of the mutation on channel activity is most apparent in the high
gain recordings, which reveal a marked increase in Na
+ channel
activity that has failed to inactivate completely over the duration of
the 200 ms test pulse. Figure 2D, which presents summary data,
shows that the F1473C mutation causes a 6-fold increase in non-
inactivating late current (INaL) measured at 200ms during pulses to
210 mV (WT: INaL=0.1+/20.01%, n=11 and F1473C:
INaL=0.63+/20.05%, n=31; p,1.5e-05), which is plotted as
the percentage of peak current.
Figure 3 summarizes experiments focusing on possible effects of
the F1473C mutation on the voltage-dependence of activation and
peak current density. Because these experiments focused on peak
and not late currents, we used extracellular solutions containing
reduced [Na
+] (Methods S1 (supplemental methods)) to ensure
adequate voltage control. Figure 3A, which presents mean peak
current voltage-relationships for WT (open triangles) and F1473C
(filled squares) channels, indicates no mutation-induced change in
mean current density. Analysis of these current voltage relation-
ships reveals no detectable change in the voltage-dependence of
activation (Figures 3B; WT: V1/2=224.8 +/21.3 mV, n=13
and F1473C: V1/2=227.2+/21.6 mV, n=7), slope factor of the
fitted Boltzmann relationships (WT: k=6.2+/20.3 and F1473C:
k=6.6+/20.2). Thus the primary functional consequence of the
F1473C mutation appears to be disruption of Na
+ channel
inactivation during prolonged depolarization such as depolariza-
tion in ventricular cells during the plateau phase of the ventricular
action potential underlying the QT interval of the ECG.
The marked increase in INaL caused by the mutation is
consistent with mutant Na
+ channel activity that can contribute
to delayed repolarization of cellular action potentials[12], but this
is not the only biophysical property altered by the mutation that
might contribute to the disease phenotype. Because mutation-
altered Na
+ channel inactivation is critical to the functional
consequences of the mutant channels on cellular electrical activity,
we next tested for effects of the F1473C mutation on steady state
inactivation which primarily reflects transitions from closed to
inactivated states (closed state inactivation), as well as the impact of
the mutation on the time course of recovery from inactivation at
negative potentials. We measured availability curves for both WT
and mutant channels using conditioning pulses of 0.5 s (not
illustrated) and 5 s (Figure 4A) using voltages that ranged from
2120 mV to 220 mV. As shown in the figure, the F1473C
mutation causes almost a +10mV depolarizing shift in the V1/2 of
Figure 4. The F1473C mutation has multiple biophysical conse-
quences. A. The F1473C mutation causes an 8.861.6 mV depolarizing
shift in the steady state availability curve. Data shown for WT (n=9,
open triangles) and F1473C (filled squares, n=25) channels. B. Mutation
at F1473C speeds the time course of recovery from inactivation as
measured at 2100 mV following a 50 ms pulse to 210 mV. WT (open
triangles, n=5) and F1473C (closed squares, n=5). C. Normalized WT
(grey) and F1473C (black) currents in response to a ramp in voltage
from 2120 mV to +40 mV (see Methods S1) over the course of 1s reveal
F1473C-enchanced inward current over a broad range of voltage.
Shown are averaged TTX-sensitive currents for WT (light grey, n=4) and
F1473C (black, n=11) channels. Note the inverted bell-shaped response
of WT channels to this protocol reveals ‘‘window’’ of current for WT
channels (see text for details).
doi:10.1371/journal.pone.0001258.g004
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F1473C: V1/2=262.4+/20.7 mV, n=25; p,1.79E-07) with
little or no change in the slope factor of the fitted Boltzmann
relationships (WT: k=6.4+/20.3 and F1473C: k=5.7+/20.2).
We illustrated the results of prolonged conditioning pulses to
ensure steady state was reached for the pharmacological experi-
ments that follow, but similar results were obtained using
conditioning pulses of 500 ms (data not shown).
The time course of recovery from inactivation was investigated
using a 50ms conditioning pulse (210 mV) to induce inactivation
followed by a test pulses after returning to 2100 mV for varying
time periods to allow time for channels to transition out of the
inactivated state. The data from these experiments, fitted by
functions with two exponential components, are summarized in
Figure 4B. The data show that the F1473C mutation causes
a significant speeding of both the fast (WT: tfast=8.4+/20.8 ms,
n=5 and F1473C: tfast=4.5+/20.6 ms, n=5; p,0.003) and
slow (WT: tslow=216.74+/239.3 ms n=5 and F1473C:
tslow=112.6+/219.8 ms n=5; p,0.04) processes by which Na
+
channels transition from inactivated to available (closed) sates. The
results summarized in Figures 2 and 4 show that the inherited
mutation makes channels reluctant to enter the inactivated state
(Figures 2C,D and 4A), and shortens the time in the inactivated
state once channels are returned to voltages in the range of
diastolic potentials (Figure 4B). Interestingly, similar results have
been reported in experiments with recombinant skeletal muscle
F1473C Na
+ channels[13]. Furthermore, although the mutation-
induced positive shift in steady-state inactivation (Figure 4A) but
not activation (Figure 3B) slightly-changes the voltage-dependence
of Na
+ channel window current, the mutation clearly increases late
currents measured over a broad ranges of voltages (Figure 4C). In
the experiments illustrated in Figure 4C, positive voltage ramps
(Methods) were imposed on HEK 293 cells expressing WT and
F1473C channels (see labels in figure), in the absence and presence
of TTX. Shown in the figure are TTX-sensitive currents for both
conditions. In response to positive voltage WT channels conduct
current over a narrow range of voltages (peaking near 240 mV in
these experiments). This type of current is referred to as ‘‘window’’
Figure 5. Relative sensitivity of peak and late F1473C channel current to three different Na
+ channel blockers. A–C. Averaged normalized currents
from F1473C channels evoked by 200 ms depolarizing currents to 210 mV at 0.5Hz in the presence and absence of 50 mM mexiletine (A, n=5),
50 mM ranolazine (B, n=15), and 10 mM flecainide (C, n=5). Traces in the presence of each drug are shown in grey and indicated by an arrow in the
inset. Drug-free traces are black. Note that the units and presentation reflect normalization to peak current under drug-free conditions. D. Bar graph
summarizes fraction of peak (grey bars) and late current (black bars) blocked by each drug. Each drug inhibited late current preferentially over peak
current (* p,,0.05). Inhibition of peak and late current was not significantly different among all drugs tested.
doi:10.1371/journal.pone.0001258.g005
SCN5A Mutation in Newborn
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relationships in this narrow voltage range. Clearly F1743C mutant
channels conduct not only over this narrow voltage range, but over
the full range of voltages that open the channels. Thus altered
window current by itself does not account for the F1473C-induced
increase in late current.
Distinct Pharmacology of F1743C Mutant Channels
The differential response of the patient to Na
+ channel blockers
prompted us to investigate the efficacy of three different
compounds, flecainide, mexiletine, and ranolazine, in correcting
the biophysical dysfunction of the F1473C mutant channel. We
selected these drugs because, in cases of other LQT-3 mutations,
each has been shown to inhibit preferentially late vs. peak Na
+
channel currents and, at least in the case of flecainide and
mexiletine, has been shown effective in treating patients carrying
LQT-3 mutations[14,15]. The three drugs (Figure 5) more
potently inhibit late vs. peak F1473C channel currents, with
roughly the same selectivity reported previously for channels
carrying the DKPQ LQT-3 mutation[16,17]. Figures 6B and 6C
reveal that, at concentrations that significantly inhibit INaL
(Figure 5), both ranolazine (50 mM) and mexiletine (50 mM
ranolazine) cause similar and significant hyperpolarizing shifts in
the voltage-dependence of steady-state inactivation for F1473C
channels (Mexiletine: 211.2 mV shift, p,0.009 and Ranolazine:
26.6 mV shift, p,0.003). These shifts in inactivation, comparable
for these two drugs, essentially restore the closed state inactivation
voltage range of WT channels to F1473C channels (Table 1). In
contrast, a flecainide concentration (10 mM) which has compara-
ble efficacy on INaL inhibition (Figure 5), has no significant effect
on the voltage-dependence of F1473C channel closed state
inactivation (Figure 6A, Table 1), consistent with previous reports
on the effect of flecainide on steady state inactivation for WT
channels[18].
Impact of the F1743C mutation and Na
+channel
blockers on Na
+ channel currents during
repolarization
Mutations that enhance Na
+ channel activity either through
altered channel kinetics as in non-equilibrium gating[19], and or
via increased late channel current[12,20], will mask outward
current during repolarization and exacerbate mutation-induced
action potential prolongation. Figure 7 summarizes experiments
designed to detect whether or not the F1473C mutation augments
inward Na
+ channel current under conditions that are similar to
repolarization of the ventricle, and further, whether or not
mexiletine and ranolazine are effective inhibitors of this current
using previously-described negative ramp voltage protocols
(Methods)[19]. Illustrated in the figure, are results of experiments
in which cells were first depolarized to +20 mV for 100 ms to
promote open state inactivation, after which repolarization to
2100 mV was imposed with a negative voltage ramp, roughly
mimicking the repolarization phase of the ventricular action
potential. Figure 7A compares the response of WT channels with
F1473C channels to this voltage protocol and several conse-
quences of the mutation are readily apparent. First, compared
with WT channels there is a very large increase in non-inactivating
current for F1743C channels over the duration of the voltage pulse
to +20 mV, confirming that the mutation-induced late current is
evident beyond the range of inactivation/activation curve overlap
(window current). Second, and importantly, the mutation induces
a large surge of inward current during the negative repolarizing
voltage ramp that will contribute greatly to delayed repolarization
of myocytes expressing this channel (see discussion of model
results). Mexiletine (Figure 7B) and ranolazine (Figure 7C) both
markedly inhibit the mutation-induced inward current during the
simulated plateau (100 ms at +20 mV) and repolarization phase
(negative ramp) in this protocol. Thus, at concentrations with
minimal effects on peak Na
+ channel currents, both of these drugs
Figure 6. Mexiletine and Ranolaziine, but not Flecainde, correct
mutation-induced voltage shift in steady state inactivation. Steady
state inactivation was measured with a 5s conditioning pulse (see
Methods S1) followed by a brief 210 mV test pulse. A. Flecainide (n=4)
did not significantly alter V1/2 or slope factor of the channel availability
curve. B–C. Mexiletine (n=5) and Ranolazine (n=9) each caused
significant hyperpolarizing shifts in the voltage-dependence of steady-
state inactivation (Table 1).
doi:10.1371/journal.pone.0001258.g006
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F1473C mutation.
Computational modeling: dramatic effects of the
F1473C mutation on ventricular action potential
duration and restoration of wild type cellular
phenotype by Na
+ channel blockers
In order to better understand the cellular phenotype caused by the
mutation, the altered channel biophysics were incorporated into
a Markov model of Na
+ channel gating[21] and then inserted into
an adult human ventricular action potential model[22], lacking
a comparable model for ventricular cells in newborns. The
sustained current observed in patch clamp experiments was
modeled as an increased probability of entering a bursting mode of
channel openings, based on the observed broad voltage-de-
pendence of mutation-enhanced late current. The steady state
inactivation shift was reproduced by altering the voltage de-
pendence of the transition between closed and closed inactivated
states which interestingly also recapitulated the observed speeding
of recovery from inactivation determined in experiments
(Figure 4B and Methods S1, Figure S-1).
Inserting the channel kinetics into a human ventricular action
potential model results in a profound prolongation of the action
potential. At a 1Hz pacing rate, steady state action potential
duration was nearly doubled (313 ms, WT vs. 588 ms, F1473C) in
the mutant (Figure 8A). Consistent with previously modeled LQT-
3 mutants with a pronounced bursting mode, an increase in rate
drastically reduced the APD difference between WT and mutant
(at 2Hz, 252 ms WT, 344 ms F1473C). To dissect the individual
contributions of the voltage shift in steady state inactivation (SSI)
and the increase in bursting, each effect was simulated in-
dependently (at 1Hz). Interestingly the SSI shift alone had no
effect on APD in the absence of bursting but in the presence of
bursting its ablation abbreviated the action potential by 42 ms to
546 ms suggesting a significant contribution of the shift in addition
to the bursting in the extremely prolonged QT intervals observed.
Figure 8B, illustrates the simulated effects of 50 mM mexiletine on
myocytes expressing the mutant channel by superimposing
computed action potentials in the absence and presence of
mexiletine (using drug block profiles in Table 1) for cells paced
at 1Hz. Also shown in the figure for comparison is the control WT
action potential of Figure 8A. Clearly, in the simulation mexiletine
greatly rescues the channel defect reducing the F1473C cellular
APD from 588ms to 386ms at 1Hz, close to the computed APD of
cells expressing WT channels.
DISCUSSION
Na
+ channel variants and inherited arrhythmias in
infants
The results of our study clearly show that the SCN5A F1473C
mutation, which was discovered as a de novo mutation in a newborn,
clearly disrupts inactivation of Nav1.5 channels in manners which
contribute to delayed repolarization in cardiac cells expressing this
channel variant. The present study adds to a growing literature
that suggests that LQTS mutations in general and LQT-3
mutations in particular, are both more prevalent and particularly
problematic in hearts of infants compared with adults[9–11,23–
26]. In a systematic study of autopsied SIDS cases Ackerman et
al[27] reported an incidence of SCN5A mutations of 2.1% and
most recently, in a survey of SIDS victims involving 201
Norewegian cases, approximately half of the gene variants linked
to LQTS were found to be SCN5A mutations[7], which is higher
than the approximately 10% incidence reported in adult LQTS
patients[28].
Several characteristics of the clinical phenotype and therapeutic
responses we report are consistent with those previously described
for LQT-3 cases in infants, including both pronounced QT
prolongation (594 ms to 740 ms[9,11,26]) and mixed efficacy in
the controlling QT prolongation and resulting arrhythmias with
Na
+ channel blockers[9,11,24,26]. For example, whereas mex-
iletine was effective at controlling both 2:1 atrioventricular (AV)
block in a newborn with an SCN5A (P1332L) mutation[11], in
a another case neither mexiletine nor flecainide was useful in long-
term control of QT prolongation in a neonate with another SCN5A
mutation (R1623Q)[9]. In a different neonate with the R1623Q
SCN5A mutation, mexiletine was initially effective in controlling
QT prolongation, but it was difficult to maintain a therapeutic
concentration, possibly due to poor absorption from the
gastrointestinal track[24]. The variable efficacy of Na
+ channel
blockers in infants with the R1623Q mutation is particularly
important in view of the fact that cellular biophysical and
pharmacological studies showed effective restoration of channel
function of this mutation by lidocaine[29].
Table 1. Effects of Na
+ channel blockers on WT and F1473C channels.
..................................................................................................................................................
Peak Current Block (%) Late Current Block (%) Inactivation V1/2 (mV) Inactivation slope factor
WT 271.2+/20.9 (9) 6.4+/20.3
WT Mexiletine 24.6+/22.7 (5) 285.5+/23.2 (4)
* 7.6+/20.6
WT Ranolazine 13.2+/23.2 (6)
1 276.1+/21.6 (5)
* 6.3+/20.4
F1473C 262.4+/20.7 (25) 5.7+/20.2
FC Flecainide 30.0+/25.6 (5) 69.0+/27.4 (5) 264.3+/21.0 (4) 6.1+/20.5
FC Mexiletine 15.3+/26.3 (5) 70.6+/23.3 (5) 273.6+/22.6 (5)
{ 7.1+/20.4
{
FC Ranolazine 27.2+/23.9 (15)
1 62.7+/23.9 (15) 269.0+/21.6 (9)
{ 6.2+/20.4
Table 1 summarizes the values for current block in both WT channels and F1473C channels in the presence of the drugs tested. Also shown is the average values of the
Boltzmann fit parameters for the steady state availability curve. Values are reported as the mean6S.E. The number in parentheses indicates the number of experiments.
Statistical significance was determined using an unpaired Student’s t test.
*p,0.03 vs WT V1/2,
{p,0.009 vs FC V1/2,
{p,0.03 vs FC slope factor,
1p,0.01 vs WT block in Ranolazine.
doi:10.1371/journal.pone.0001258.t001
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consequences
Our results indicate that, like many of the previously-reported
SCN5A mutations in young children, the F1473C mutation, which
appeared de novo in the proband of this study, causes marked
changes in Nav1.5 channel inactivation that are predicted to have
severe physiological consequences. The most obvious effect of the
mutation is an increase in late Na
+ channel current over a broad
range of cellular membrane potentials, an effect similar to other
previously-described LQT-3 mutations such as the DKPQ
mutation[30]. In addition, the F1473C mutation speeds recovery
from inactivation, causes a positive shift in the voltages over which
closed-state inactivation transitions occur, and produces a positive
shift in the voltage-range over which steady-state inactivation and
activation overlap (window current). Each of these perturbations
alone has been shown to be sufficient to account for delayed
repolarization for other LQT-3 mutations[19,31]. Thus, it is not
surprising that the patient carrying the F1473C mutation
presented with extreme QT prolongation (approximately
800 ms). The concomitant 2:1 heart block was very likely caused
by conduction block in the ventricle due to extremely prolonged
ventricular action potentials, similar to the suggested mechanism
of 2:1 heart block caused by another SCN5A mutation in
a newborn[24]. Thus, similar to the recent report of Wang et
al[8], we find that the F1473C mutation disrupts Na
+ channel
inactivation with severe predicted cellular phenotypic conse-
quences. However, our analysis also suggests that the F1473C
mutation-induced changes in Na
+ channel activity by themselves
are not sufficient to explain either the patient’s disease phenotype
or response to the different Na
+ channel blockers.
Impact of ionic and genetic background on
phenotype of F1473C carriers: insight from
computational modeling
Incorporation of the F1473C mutation-induced biophysical
changes in channel gating described above into a model of an
adult human ventricular myocyte[22] yielded simulated action
potentials with markedly delayed repolarization that are qualita-
tively similar to the patient’s phenotype. Simulations suggest both
an increase in pacing rate and Na
+ channel blockers as beneficial
in recovering channel function consistent with the successful
arrhythmia management obtained by pacing and high-dose
mexiletine. The simulations also suggest that the absence of an
effect of flecainide on Na
+ channel closed state availability
contributes to the ineffectiveness of this drug on the treatment of
the proband.
Limitations of the analysis and implications for roles
of age and genetic background
Despite these important insights there are limitations that must be
considered. First, the computational model is based on adult
cardiac electrophysiology, because, at this time, appropriate
models have not been developed for infants. This very likely
affects the background of repolarizing potassium channel currents
against which the F1743C sodium channel is simulated[32,33].
Differences in resting potentials that may arise as a consequence of
age-related repression of potassium channels[34] would likely
exacerbate differences in drug action that affect closed state
inactivation, in comparing flecainide and mexiletine effects in the
proband. Additionally, flecainide, but not mexiletine, has been
reported to inhibit IKr potassium channels for which HERG forms
the principal a subunit[35,36]. This effect might be tolerated in
treatment of adult LQT-3 mutation carriers but it might offset the
effects of flecainide on F1473C mutant channel activity in the
mutation carrier due to his age and genetic background. Finally,
the genetic background of the newborn must be considered. The
Figure 7. Mexiletine and ranolazine inhibit F1473C channel activity
during repolarization. Inward currents were measured in response to
a pulse to +20 mV for 100 ms followed by repolarization to 2100 mV at
21.6 V/sec (negative ramp) (see Methods S1). A. F1473C channels,
relative to WT channels, show a very large increase in non-inactivating
current for the duration of the voltage pulse to +20 mV and also cause
a large surge of inward current during the negative voltage ramp. B–C.
Mexiletine (B) and ranolazine (C) inhibit the mutation-induced
repolarizing inward current (Mexiletine block of repolarization phase
peak current=82.1+/20.2%, n=7; Ranolazine block of repolarization
phase peak current=83.1+/20.2%, n=4).
doi:10.1371/journal.pone.0001258.g007
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a common polymorphism KCNH2 (K897T) [37–40]. This poly-
morphism has been studied extensively and found to affect HERG
channel function, but there is no clear consensus on whether the
altered function favors QT prolongation, shortening, or a combi-
nation of the two depending on physiological conditions such as
heart rate[39–42]. Importantly, the mother of the proband,
homozygous for K897T KCNH2 was unaffected (normal QTc).
Thus, it is possible that alteration in repolarization reserve via
K897T HERG channels, while insufficient to affect electrical
activity in the mother, may contribute to QT prolongation and,
again to distinction in flecainide’s activity due to this drug’s effects
on the IKr channel. This is likely to be the case as the K897T
KCNH2 has been reported to be a genetic modifier of latent LQTS
in a carrier of K897T KCNH2 and a another low-penetrant
KCNH2 mutation[42].
Conclusions
In summary, we report and present biophysical and pharmaco-
logical analysis of a novel de novo SCN5A mutation that was
discovered in a newborn diagnosed with severe LQTS providing
additional evidence of the importance of Na
+ channel mutations in
inherited arrhythmias in newborns. Further, the very pronounced
QT prolongation in the proband and the distinct therapeutic
effectiveness of different Na
+ channel blockers used to treat the
patient were in large part due to the Na
+ channel dysfunction
caused by the mutation. However, our analysis suggests that the
patient’s genetic background and age impact both the severity of
the disease phenotype and the differences in the effectiveness of
two sodium channel blockers, flecainide and mexiletine as
therapeutic agents. Our results underscore that mutation-induced
changes in channel gating are necessary but not sufficient to
explain the phenotypic and therapeutic responsiveness of patients
harboring specific gene mutations. While distinct biophysical
changes in channel properties will account for some drug
discrimination in patients [43] other factors, such as the presence
of polymorphisms in other channels (as in our patient) and age-
related changes in cell physiology, must also be taken into account.
MATERIALS AND METHODS
Genetics
The proband was bi-directionally sequenced for all the coding
exons of KCNE1, KCNE2, KCNH2, KvLQT1, and SCN5A. 100
normal Caucasian controls with normal QT intervals on EKG and
without a clinical history of syncope, presyncope or arrhythmias
were screened for the F1473C SCN5A.
Electrophysiology
Site-directed mutagenesis was done on NaV1.5 in pcDNA3.1 using
the Quik Change site-directed mutagenesis kit (Stratagene). Whole
cellrecordings were made on Human Embryonic Kidney(HEK)293
cells expressing Wild type and mutant NaV1.5 channels along with
hb1 subunits (Lipofectamine, Invitrogen) as previously described
[31]. Solutions and voltage protocols are detailed in the supplemental
materials (Methods S1). Mexiletine and Flecainide were provided by
Sigma (St Louis, Missouri). Ranolazine was provided by CVT
Therapeutics (Palo Alto, CA). Membrane currents were measured
with Axopatch 200B amplifiers (Axon Instruments, Foster City, CA).
Capacitance and series resistance compensation were carried out
using analog techniques according to the amplifier manufacturer
(Axon Instruments, Foster City, CA). PClamp8 (Axon Instruments)
was used for data acquisition and initial analysis. Analysis was carried
out in Excel (Microsoft), Origin 7.0 (Microcal Software, North-
ampton, MA), and programs written in Matlab (The Mathworks,
N a t i c k ,M A ) .A n a l y z e dd a t aa r es h o w na sm e a n+/2 S.E.M.
Statistical significance was determined in some cases using the
unpaired Student’s t test and in others using the paired Student’s t
test; p,0.05 was considered statistically significant.
Computational Methods
Sodium channel kinetics were modeled in the context of a Markov
model based on previous work of Clancy et al,[21] and described
in detail in Methods S1. The Markov model is then inserted into
a human ventricular action potential model[22] and paced with
twice threshold stimuli at a variety of pacing intervals to examine
the cellular consequence of the mutation.
Figure 8. Simulation of the impact of the F1473C mutation and its modulation by mexiletine on the ventricular action potential. A. Shown are
the computed action potentials for the F1473C mutant (black trace) as compared to WT (blue trace) at 1Hz. Also shown is the contribution of F1473C
late current alone to action potential prolongation, without changing the channel steady state availability (red trace). B. The simulations show the
drug markedly rescues the channel function reducing the F1473C APD from 588 ms to 386 ms.
doi:10.1371/journal.pone.0001258.g008
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Found at: doi:10.1371/journal.pone.0001258.s001 (0.05 MB
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